Knight Therapeutics, Inc. (GUD) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Knight Therapeutics, Inc.

BioSyent, Inc.

Fennec Pharmaceuticals, Inc.

HLS Therapeutics, Inc.

InnoCan Pharma Corp.

Ayr Wellness, Inc.

NervGen Pharma Corp.

Defence Therapeutics Inc

Arch Biopartners, Inc.

Cybin, Inc.

Mindset Pharma, Inc.

Why is Knight Therapeutics, Inc. ?

With a growth in Operating Profit of 64.57%, the company declared Outstanding results in Mar 26

OPERATING CASH FLOW(Y) Highest at CAD 104.53 MM
NET SALES(Q) Highest at CAD 148.44 MM
INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost

With ROE of 1.37%, it has a expensive valuation with a 1.16 Price to Book Value

The stock is trading at a discount compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of 51.03%, its profits have risen by 127% ; the PEG ratio of the company is 0.7

Market Beating performance in long term as well as near term

Along with generating 51.03% returns in the last 1 year, the stock has outperformed S&P/TSX 60 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Knight Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Knight Therapeutics, Inc. for you?

Medium Risk, High Return

Absolute

Risk Adjusted

Volatility

Knight Therapeutics, Inc.

52.5%

2.48

25.58%

S&P/TSX 60

29.63%

2.33

12.07%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

20.64%

EBIT Growth (5y)

22.85%

EBIT to Interest (avg)

-0.43

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.11

Sales to Capital Employed (avg)

0.46

Tax Ratio

28.80%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.15%

ROCE (avg)

0.49%

ROE (avg)

1.02%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.16

EV to EBIT

61.87

EV to EBITDA

11.36

EV to Capital Employed

1.18

EV to Sales

1.67

PEG Ratio

0.66

Dividend Yield

ROCE (Latest)

1.91%

ROE (Latest)

1.37%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

28What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CAD 112.9 MM

NET SALES(HY)

At CAD 292.65 MM has Grown at 49.74%

ROCE(HY)

Highest at 1.9%

INTEREST COVERAGE RATIO(Q)

Highest at 1,127.86

PRE-TAX PROFIT(Q)

At CAD 7.56 MM has Grown at 167.49%

NET PROFIT(Q)

At CAD 6.3 MM has Grown at 133.93%

RAW MATERIAL COST(Y)

Fallen by -23.34% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 4.33 times

-5What is not working for the Company

INTEREST(HY)

At CAD 4.77 MM has Grown at 15.4%

Here's what is working for Knight Therapeutics, Inc.

Interest Coverage Ratio

Highest at 1,127.86

in the last five periods

MOJO Watch

The company's ability to manage interest payments is improving

Operating Profit to Interest

Pre-Tax Profit

At CAD 7.56 MM has Grown at 167.49%

over average net sales of the previous four periods of CAD 2.83 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CAD MM)

Net Profit

At CAD 6.3 MM has Grown at 133.93%

over average net sales of the previous four periods of CAD 2.69 MM

MOJO Watch

Near term Net Profit trend is very positive

Net Profit (CAD MM)

Net Sales

At CAD 292.65 MM has Grown at 49.74%

Year on Year (YoY)

MOJO Watch

Near term sales trend is positive

Net Sales (CAD MM)

Operating Cash Flow

Highest at CAD 112.9 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CAD MM)

Debtors Turnover Ratio

Highest at 4.33 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -23.34% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Knight Therapeutics, Inc.

Interest

At CAD 4.77 MM has Grown at 15.4%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CAD MM)